Side Effects: There were no serious incidents of hypoglycaemia (too little blood sugar) reported, nor were there any maglinancies in the thyroid gland or reports persistent hyperglycaemia (too much blood sugar) 8% of patients across all Retatrutide groups collectively did not continue treatment because of an adverse event The most commonly reported adverse events in people taking Retatrutide were gastrointestinal in nature (constipation, diarrhea, vomiting, nasuea), were mild to moderate in severity, and happened more often in people taking larger doses of Retatrutide All in all, patients on Retatrutide experienced a dramatic improvement in insulin sensitivity and any observed side effects were not significantly different in severity, type or frequency compared to the Phase 2 trial for obesity
doi: 10.1111/dom.13531 28 KalraSDasSZargarAH
starting doses of Wegovy and Zepbound would cost Medicaid programs $350/month Duration : five-year model, concluding December 2031 Lifestyle support : all enrollees receiving GLP-1s for weight management must receive access to a lifestyle support program provided by the manufacturer at no cost Prior authorization : still required
Semin Nephrol
This physician-led review explains what the evidence actually shows about TRT and cardiovascular health, where earlier concerns came from, and how TRT can be approached responsibly for men in Minneapolis
This approach can also help you see if a lower maintenance dose would work for you
